Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 3,019 shares at $68.54 ($210K) on 2026-02-19, disclosed to the SEC on 2026-02-23.
Seasonal sale ($210k) by Executive VP AND CLO — this insider has traded PTCT in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $68.54 | 212 | $15K | 6.9% |
| 2 | $68.54 | 588 | $40K | 19.2% |
| 3 | $69.82 | 590 | $41K | 19.6% |
| 4 | $69.82 | 1,629 | $114K | 54.2% |
| Total | $69.48 avg | 3,019 | $210K | 100% |
| Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |
| PTCT | SELL | 2026-05-19 | $203K | — | Filing → |
| PTCT | SELL | 2026-05-12 | $280K | — | Filing → |